Hayden Michael R

Average Profitability
38.35%
Insider Buys Quantity
13
Insider Buys Sum
$5.33M
Insider Sells Quantity
1
Insider Sells Sum
$2.55M

Insider Activity of Hayden Michael R

According to the SEC Form 4 filings, Hayden Michael R, being in a position of

  1. director at Ionis Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 5000 shares for $181,079, and sold 0 shares,
    over all time since 2024-12-23, has bought 5000 shares for $181,079, and sold 0 shares.

The largest purchase of all time was on 2020-12-15 and amounted to 147330 shares of AbCellera Biologics Inc. for $2.95M.

The largest sale of all time was on 2021-06-22 and amounted to 100000 shares of AbCellera Biologics Inc. for $2.55M.

Biography of Hayden Michael R

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$181,0791100
Sells
$000

Comparison of Insiders on Amount of Buys and Sells

2024-12-23PurchaseIonis Pharmaceuticals, Inc.
IONS
director
5,000
0.0032%
$36.22$181,079-8.74%
2023-09-22PurchaseAbCellera Biologics Inc.
ABCL
director
20,000
0.0066%
$4.91$98,200-14.3%
2023-08-08PurchaseAbCellera Biologics Inc.
ABCL
director
30,000
0.0104%
$5.90$177,000-23.77%
2023-03-28Purchase89bio, Inc.
ETNB
director
61,538
0.112%
$16.15$993,839-10.96%
2022-04-25Purchase89bio, Inc.
ETNB
director
10,000
0.0475%
$2.67$26,700+196.74%
2022-04-25Purchase89bio, Inc.
ETNB
director
20,000
0.0951%
$2.67$53,400+196.74%
2022-04-07Purchase89bio, Inc.
ETNB
director
10,000
0.0496%
$3.48$34,750+120.78%
2022-04-07Purchase89bio, Inc.
ETNB
director
20,000
0.0993%
$3.48$69,500+120.78%
2022-03-30Purchase89bio, Inc.
ETNB
director
6,250
0.0309%
$3.62$22,625+74.44%
2022-03-30Purchase89bio, Inc.
ETNB
director
12,500
0.0618%
$3.62$45,250+74.44%
2021-06-22SaleAbCellera Biologics Inc.
ABCL
director
100,000
0.0424%
$25.50$2.55M-36.66%
2020-12-15PurchaseAbCellera Biologics Inc.
ABCL
director
147,330
0.0394%
$20.00$2.95M-51.21%
2019-11-11Purchase89bio, Inc.
ETNB
director
37,500
1.2305%
$16.00$600,000+28.8%
2017-08-14PurchaseXenon Pharmaceuticals Inc.
XENE
director
30,000
0.1833%
$2.75$82,494+44.6%
Total: 14
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.